About Aerpio.

The company behind the science.

Dhaval Desai - Vice-President, Medical Affairs

Dr. Desai arrived at Aerpio with 15 years of experience in marketing, medical affairs and clinical development. He brings hands on pre and post-launch experience in the retina therapeutic space. Prior to joining Aerpio, Dr. Desai worked at ThromboGenics, where he held roles in marketing and medical affairs. At ThromboGenics, he was an integral member of the pre-launch team and led the market development efforts. He also led the team that achieved Jetrea® (ocriplasmin) regulatory approval by the FDA for the treatment of symptomatic VMA. During this time, he worked closely with and developed strong relationships with many preeminent retinal physicians. Previously, Dr. Desai worked at Onyx Pharmaceuticals where he was integral in the early development of Nexavar® (sorafenib) for thyroid cancer. Dr. Desai obtained his Pharm.D. from, and completed his postdoctoral fellowship at, Rutgers University.

LinkedIn Connect with Dhaval